Amarin Corp Plc (AMRN)

[ziploc_1]

rose...QUOTE" the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of reducing or preventing small dense LDL ("sdLDL") oxidation in a subject, the method comprising administering to the subject a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
Inventors: Mason; Richard Preston (Bedminster, NJ)"

Wasn't Mason also working on a study to show that Amarin's patented gelatin capsule prevented oxidation of the EPA within?...This would tie into the idea that less oxidized EPA produces less oxidized small dense LDL, which then, in turn, produces a reduction in CVD events....Wouldn't this be evidence that gV, with an inferior capsulation, does NOT have the same effectiveness as Vascepa in reducing CVD events...a defect in gV that the FDA has not dealt with to date....and a reason why I declined to approve my pharmacist's offer to substitute gV for my Vascepa?